CN114008048A - 外核苷酸酶抑制剂及其使用方法 - Google Patents

外核苷酸酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN114008048A
CN114008048A CN202080045115.6A CN202080045115A CN114008048A CN 114008048 A CN114008048 A CN 114008048A CN 202080045115 A CN202080045115 A CN 202080045115A CN 114008048 A CN114008048 A CN 114008048A
Authority
CN
China
Prior art keywords
compound
amino
cancer
alkyl
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080045115.6A
Other languages
English (en)
Chinese (zh)
Inventor
陈丽晶
R·J·比洛多
J·李
T·F·斯坦顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deqi Medical Co ltd
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CN114008048A publication Critical patent/CN114008048A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080045115.6A 2019-06-20 2020-06-18 外核苷酸酶抑制剂及其使用方法 Pending CN114008048A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864031P 2019-06-20 2019-06-20
US62/864,031 2019-06-20
PCT/US2020/038395 WO2020257429A1 (en) 2019-06-20 2020-06-18 Ectonucleotidase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CN114008048A true CN114008048A (zh) 2022-02-01

Family

ID=74040909

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045115.6A Pending CN114008048A (zh) 2019-06-20 2020-06-18 外核苷酸酶抑制剂及其使用方法

Country Status (8)

Country Link
US (1) US20220363709A1 (https=)
EP (1) EP3986894A4 (https=)
JP (1) JP2022537358A (https=)
KR (1) KR20220024629A (https=)
CN (1) CN114008048A (https=)
AU (1) AU2020294724A1 (https=)
CA (1) CA3143496A1 (https=)
WO (1) WO2020257429A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
AU2019288495B2 (en) 2018-06-21 2024-02-08 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
HUE072504T2 (hu) 2019-10-30 2025-11-28 Oric Pharmaceuticals Inc CD73-inhibitorok
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
KR102775989B1 (ko) * 2022-11-01 2025-03-04 윤주호 콜치신과 메트포르민을 유효성분으로 하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
WO2015164573A1 (en) * 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
TWI767937B (zh) * 2016-09-09 2022-06-21 美商卡利泰拉生物科技公司 外核苷酸酶抑制劑及其使用方法
JP7138351B2 (ja) * 2016-12-22 2022-09-16 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
AU2019288495B2 (en) * 2018-06-21 2024-02-08 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
EP3986894A4 (en) 2023-08-09
CA3143496A1 (en) 2020-12-24
AU2020294724A1 (en) 2022-01-20
KR20220024629A (ko) 2022-03-03
EP3986894A1 (en) 2022-04-27
WO2020257429A1 (en) 2020-12-24
US20220363709A1 (en) 2022-11-17
JP2022537358A (ja) 2022-08-25

Similar Documents

Publication Publication Date Title
CN114008048A (zh) 外核苷酸酶抑制剂及其使用方法
US11208414B2 (en) Ectonucleotidase inhibitors and methods of use thereof
US11034715B2 (en) Ectonucleotidase inhibitors and methods of use thereof
JP7538047B2 (ja) エクトヌクレオチダーゼ阻害剤及びその使用方法
HK40013556B (en) Ectonucleotidase inhibitors and methods of use thereof
HK40017040A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40013556A (en) Ectonucleotidase inhibitors and methods of use thereof
BR112019012327B1 (pt) Composto inibidor de ectonucleotidase, composição farmacêutica que compreende o mesmo, método in vitro de inibição de cd73 em uma célula e uso do dito composto para o tratamento de câncer
EA039042B1 (ru) Ингибиторы эктонуклеотидазы и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230519

Address after: Kowloon, Hongkong, China

Applicant after: Deqi Medical Co.,Ltd.

Address before: California, USA

Applicant before: CALITHERA BIOSCIENCES, Inc.

TA01 Transfer of patent application right